Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong SAR, China.
J Intern Med. 2022 Jun;291(6):864-869. doi: 10.1111/joim.13453. Epub 2022 Feb 1.
Post-marketing pharmacovigilance data are scant on the safety of Covid-19 vaccines among people with previous SARS-CoV-2 infection compared with ordinary vaccine recipients. We compared the post-vaccination adverse events of special interests (AESI), accident and emergency room (A&E) visit, and hospitalization between these two groups.
We conducted a retrospective cohort study using a territory-wide public healthcare database with population-based vaccination records in Hong Kong.
In total, 3922 vaccine recipients with previous SARS-CoV-2 infection and 1,137,583 vaccine recipients without previous SARS-CoV-2 infection were included. No significant association was observed between previous SARS-CoV-2 infection and AESI or hospitalization. Previous SARS-CoV-2 infection was significantly associated with a lower risk of A&E visit (CoronaVac: hazard ratios [HR] = 0.56, 95% confidence intervals [CI]: 0.32-0.99; Comirnaty: HR = 0.62, 95% CI: 0.47-0.82).
No safety signal of Covid-19 vaccination was detected from the comparison between vaccine recipients with previous SARS-CoV-2 infection and those without infection.
与普通疫苗接种者相比,有既往 SARS-CoV-2 感染史的人群接种新冠疫苗后的安全性的上市后药物警戒数据较少。我们比较了这两组人群的疫苗接种后特殊关注不良事件(AESI)、急诊室(A&E)就诊和住院情况。
我们使用香港全港公共医疗数据库进行了一项回顾性队列研究,该数据库具有基于人群的疫苗接种记录。
共纳入 3922 名有既往 SARS-CoV-2 感染史的疫苗接种者和 1137583 名无既往 SARS-CoV-2 感染史的疫苗接种者。既往 SARS-CoV-2 感染与 AESI 或住院无显著相关性。既往 SARS-CoV-2 感染与 A&E 就诊风险较低显著相关(科兴:风险比 [HR] = 0.56,95%置信区间 [CI]:0.32-0.99;辉瑞:HR = 0.62,95% CI:0.47-0.82)。
在有既往 SARS-CoV-2 感染史的疫苗接种者和无感染史的疫苗接种者之间进行比较,未发现新冠疫苗接种的安全性信号。